With an experienced team composed of experts in organic chemistry, drug development, medicinal cannabis characterization, clinical research, regulatory and compliance in conjunction with local and central authorities, institutes and institutions, CannaPhytica BioMed is putting its best foot forward in an endeavor to bring pharmaceutical grade products to the German market, and export to the larger other European markets.

Our team is working hard to have its first methods patented in 2022 and creating a few APIs for the pharma industry.